Amgen (AMGN): FY25 Q4 earnings call, Feb 3, 2026
No Kalshi or Polymarket word markets were listed for Amgen’s Feb 3, 2026 earnings call (FY25 Q4). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
3 matches for “Tavneos”; 3 quoted, at least 25 words apart.
…not well controlled. And has limited therapeutic options. We remain confident that Tavneos is an important and effective medicine based on clinical data, real-world evidence,…
…You may wanna just start at the high altitude, remind people what Tavneos is say a few words about the disease that it addresses. It's…
…a receptor blocker, and so it blocks complement mediated destruction. We acquired Tavneos from ChemoCentryx in 2022 after it had been on the market market…
Agents: this page as TSV at /api/v1/appearances/amgen:2026-02-03:earnings_call · words: /api/v1/brief?appearance=amgen:2026-02-03:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP